Objective The aim of TA101GOCLIN Project is to take TA101 into the clinical stage of development for rheumatoid arthritis and prepare the product for a novel mode of administration in the market of biologic therapeutics.Rheumatoid Arthritis is still today a debilitating disease with an unmet medical need for effective and reasonably priced treatments despite much effort to cure or control the disease. TA101 is a small domain antibody that is being developed for the treatment of rheumatoid arthritis and has passed through preclinical efficacy studies with much success. TA101 will now undergo an upscaling process of production to enter clinical trials. TA101GOCLIN project is within the scope of the clinical development of TA101 and is aimed at providing safety data in humans through a clinical trial of Phase Ia and Ib.Concomitantly, TA101GOCLIN will develop a novel mode of administration for TA101 to be used after project end. This will provide a major competitive advantage for the product already during development stages. The innovative administration will use microneedle patches, a new method that allows the autonomous administration of the drug through the skin without the pain of conventional injections.To achieve the above mentioned objectives, TA101GOCLIN gathered three competitive SMEs from Portugal, Belgium and The Netherlands. TechnoPhage, Q-Biologicals and MyLife Technologies, respectively, will be responsible for developing the clinical data of Phase I for TA101, develop an upscale method for production of the drug, and develop the microneedle device for administration of TA101.Overall, TA101GOCLIN holds the promise that an innovative product for the treatment of Rheumatoid Arthritis will enter the clinical phases of development with the confidence that the technologies that are at its base will create a new solution for the patients, with the major benefits of efficacy, safety, convenience and affordability. Fields of science medical and health sciencesclinical medicinerheumatology Programme(s) FP7-SME - Specific Programme "Capacities": Research for the benefit of SMEs Topic(s) SME-2013-1 - Research for SMEs Call for proposal FP7-SME-2013 See other projects for this call Funding Scheme BSG-SME - Research for SMEs Coordinator TECHNOPHAGE INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SA EU contribution € 966 064,40 Address AVENIDA PROFESSOR EGAS MONIZ EDIFICIO EGAS MONIZ PISO 2 SALA A 8 1649 028 LISBOA Portugal See on map Region Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Sofia Corte-Real (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (6) Sort alphabetically Sort by EU Contribution Expand all Collapse all Q-BIOLOGICALS NV Belgium EU contribution € 274 888,50 Address TECHNOLOGIEPARK 4 9052 Gent See on map Region Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Annie Van Broekhoven (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data MICROCREATE BV Netherlands EU contribution € 6 499,20 Address RECHTERLAAN 3 7535 CH ENSCHEDE See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact K Ma (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data SGS BELGIUM NV Belgium EU contribution € 2 000,00 Address NOORDERLAAN 87 2030 ANTWERPEN See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Antoine Briffaux (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data ADHEXPHARMA France EU contribution € 8 787,00 Address RUE DE LUBECK 30 75016 Paris See on map Region Ile-de-France Ile-de-France Paris Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Thomas Daniel-Robin (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data ARTES Biotechnology GmbH Germany EU contribution € 17 600,00 Address Elisabeth-Selbert-Str. 9 40764 Langenfeld See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Michael Piontek (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data AMSPAR BV Netherlands EU contribution € 82 089,00 Address BELLAMYSTRAAT 27 D 1053BG AMSTERDAM See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Pieter Vos (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data